|
Cochrane review data used as the basis for this analysis |
||||||
| Donepezil |
Rivastigmine |
Galantamine |
||||
|
|
||||||
| Daily dose |
5 mg |
10 mg |
1–4 mg |
6–12 mg |
16 mg |
24 mg |
| Efficacy* |
-1.86 |
-2.90 |
-0.84 |
-2.09 |
-3.10 |
-3.29 |
| 95% CI |
-2.60, -1.11 |
-3.65,-2.16 |
-1.48, -0.19 |
-2.65, -1.54 |
-4.13, -2.07 |
-3.92, -2.65 |
| Beta† |
-0.071 |
-0.106 |
-0.036 |
-0.091 |
-0.105 |
-0.124 |
| 95% CI |
-0.099, -0.042 |
-0.133, -0.079 |
-0.067, -0.008 |
-0.115, -0.067 |
-0.14 -0.070 |
-0.147, -0.100 |
| Withdrawal‡ |
1.02 |
1.36 |
1.01 |
1.95 |
1.34 |
1.51 |
| 95% CI |
0.78, 1.33 |
1.10,1.70 |
0.80, 1.27 |
1.65, 2.32 |
0.95, 1.89 |
1.23, 1.87 |
|
* measured in terms of the weighted difference in mean cognitive change on the ADAS-cog comparing treatment to placebo † coefficient for variable effect analysis calculated as the efficacy divided by the mean baseline score ‡ relative risk of withdrawing from treatment, compared to placebo patients | ||||||
Caro et al. BMC Geriatrics 2003 3:6 doi:10.1186/1471-2318-3-6 |
||||||